Glomerulonephritis as a disease category is one of the leading causes of end-stage renal disease in the Western world and is associated with increased morbidity and mortality. Th e most aggressive form of glomerulonephritis with the worst clinical outcome is rapidly progressive glomerulonephritis (RPGN). 1 RPGN represents a heterogeneous collection of disease entities that are characterized by immunemediated renal damage, consisting of a specifi c immune reaction followed by an eff ector phase of infl ammation. Th is pathophysiological concept is the current rationale for unspecifi c immunosuppressive therapy with corticosteroids and cytotoxic agents; 1 however, the missing specifi city of these therapeutic regimes and frequently disabling side eff ects are the main reasons for the urgent need to develop new and more specifi c individual therapeutic strategies. In recent years, very few innovative induction therapies for RPGN have been established in clinical practice; these include mycophenolate mofetil for lupus nephritis 2 and, very recently, rituximab for ANCA-associated glomerulonephritis. 3 Green tea has been considered a healthy beverage since the beginning of its history, used in traditional Chinese medicine as a treatment for various disease conditions, and to prolong life in general. 4 More recent investigations on green tea extracts, and more specifi cally the green tea component ( − )-epigallocatechin-3-gallate (EGCG), have suggested that these compounds mediate protection from prostate and breast cancer, as well as cardiovascular disease. 5 However, in vivo evidence to support their benefi cial eff ect in immunemediated diseases is limited. In experimental models of multiple sclerosis 6 and Sj ö gren ' s syndrome, 7 application of EGCG has been shown to reduce the oxidative stress response and production of infl ammatory mediators, resulting in amelioration of inflammation and improved outcome. With respect to renal disease, the indisputable ability of this compound to protect from oxidative stress has so far been applied only to models of kidney injury, such as cisplatin-induced nephrotoxicity 8 and diabetic nephropathy. 9 Th us, the identifi cation of new molecular targets that may be exploited for therapeutic intervention in crescentic glomerulonephritis is a priority in nephrology, with emphasis on minimizing the side eff ects associated with drug toxicity and immunosuppression. Most of the research in this fi eld relies on animal models of crescentic glomerulonephritis, of which nephrotoxic nephritis (NTN) is by far the best characterized. 10 In mice, NTN is induced by injection of a heterologous antibody raised in sheep or rabbits that binds to the murine glomerular basement membrane; this induces a xenogenic immune response, resulting in immune-mediated glomerular damage, crescent formation, and tubulointerstitial leukocyte infi ltration, a pathology that closely resembles human cres centic glomerulonephritis. 10 Peng and colleagues 11 (this issue) now introduce the green tea component EGCG as a potential therapeutic compound for immune-mediated glomerulonephritis. Using the murine NTN model (here named murine anti-GBM glomerulonephritis), they show that oral administration of EGCG ameliorates the clinical course of the nephritis. Continuous treatment with EGCG, started 2 days before induction of NTN, substantially reduced crescent formation, proteinuria, and loss of renal function at day 15. Th is improved clinical outcome was accompanied by less glomerular and tubulointerstitial infi ltration of macrophages and T cells. The authors convincingly demonstrate that EGCG therapy ameliorates the oxidative stress response that contributes to the development of immune-mediated kidney injury in nephritic mice. Th e increased levels of markers for oxidative stress detected in kidney tissue and urine of vehicle-treated animals with NTN were found to be normal in the EGCG-treated group. In further experiments, the authors analyzed various enzymes involved in the metabolism of reactive oxygen species (ROS). In the infl amed kidneys of mice with NTN, they found a pattern consistent with increased ROS generation along with a reduced capacity for ROS degradation. Th is deleterious shift in renal ROS metabolism was counteracted by EGCG therapy. In line with these data, other targets that are supposedly downstream of the oxidative response were also downregulated in the therapeutic group. Increased levels of myeloperoxidase and inducible nitric oxide synthase that generate highly cytotoxic hypochloric acid and nitric oxide metabolites, respectively, were reversed by EGCG. Furthermore, activity of the central infl ammatory transcription factor nuclear factor-B and the chemoattractant osteopontin was inhibited, providing a possible explanation for the reduced leukocyte recruitment to the kidney that is observed under EGCG therapy.
The mechanisms by which EGCG administration is presumed to mediate its anti-inflammatory effect in immunemediated glomerulonephritis are summarized in Figure 1 .
In a second set of experimental mice, the authors identify the anti-infl ammatory transcription factor peroxisome proliferator-activated receptor (PPAR ) as another potential target of the pluripotent green tea compound. Th e PPAR level, found to be markedly downregulated in the kidneys of vehicle-treated nephritic mice, was restored by EGCG treatment, suggesting that PPAR activation might be crucial for its benefi cial eff ects. To underline the importance of PPAR for EGCG-mediated protection, the authors applied a PPAR antagonist together with EGCG to mice with NTN. In line with the hypothesis, concomitant treatment almost completely abrogated the beneficial effects of the EGCG therapy in terms of kidney function and histo pathological injury.
As in many therapeutic studies based on animal models, the data presented so far are hampered by diff erences in the disease course; whereas the mouse model requires a pretreatment episode prior to the induction of the disease, human autoimmune diseases develop chronically, and patients commonly have a long history of disease at the time of diagnosis. To provide further evidence for the potential benefits of EGCG as a therapeutic compound for human RPGN, the authors performed another set of experiments in which they initiated EGCG therapy aft er full-blown nephritis had developed. In these experiments they showed that treatment with EGCG from day 7 aft er induction of NTN to day 28 was also able to protect from renal tissue injury and loss of renal function. Perhaps most importantly, the delayed treatment reduced the lethality from more than 40 % to 10 % .
In summary, the study of Peng and colleagues 11 provides the fi rst experimental evidence that green tea extracts are of therapeutic value in the treatment of a mouse model of RPGN, and hopefully in humans in the future. This treatment strategy could be particularly attractive as green tea extracts have been shown to modulate the infl ammatory cascade by multiple mechanisms, and are believed to have a favorable safety profi le. 12 However, future studies to evaluate therapeutic EGCG application in humans are needed to investigate whether this innovative approach can be translated to treatment of patients with glomerulonephritis in clinical practice.
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